An independent two-stage DCF analysis by a frontier AI model.
Humana is deeply entrenched in the Medicare Advantage market, uniquely positioned to benefit from the aging US population. However, recent quarters have revealed significant pressure from elevated medical utilization rates and tightening government reimbursement policies.
Despite these near-term headwinds, Humana's scale and focus on value-based care models provide a solid foundation for long-term cash generation. The current valuation reflects much of this pessimism, suggesting the stock is trading near its fair intrinsic value, assuming management can successfully navigate the current cost environment.
A 5% growth rate is assumed, reflecting the structural demographic tailwinds of an aging population balanced against near-term margin pressures and regulatory uncertainties in the Medicare Advantage space.
A 9% discount rate is used, reflecting the company's relatively low beta of 0.41 but elevated regulatory risks and recent earnings volatility associated with higher medical costs.
A 2.5% terminal growth rate aligns with long-term macroeconomic growth expectations and the steady, albeit regulated, nature of the healthcare insurance industry.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $213.32 | $180.50 | $156.43 | $138.03 | $123.50 |
| 2.0% | $234.65 | $195.54 | $167.61 | $146.66 | $130.36 |
| 2.5% | $260.72 | $213.32 | $180.50 | $156.43 | $138.03 |
| 3.0% | $293.31 | $234.65 | $195.54 | $167.61 | $146.66 |
| 3.5% | $335.21 | $260.72 | $213.32 | $180.50 | $156.43 |
■ Undervalued vs current price ■ Overvalued vs current price
The 5% projection balances the long-term demographic tailwinds of an aging population enrolling in Medicare Advantage against near-term pressures from rising medical costs and challenging government reimbursement rates.
The primary risk lies in adverse regulatory changes to the Medicare Advantage program, particularly reductions in base payment rates or changes to the risk adjustment model, which could severely impact profitability.
Humana's investments in value-based care are expected to help control long-term medical costs and improve patient outcomes, supporting the assumption of steady, sustainable cash flows over the long term despite current margin pressures.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.